Pfizer Patent Suits Seek to Block Competitors’ Dermatitis Drugs

April 17, 2026, 8:08 PM UTC

Pfizer Inc. filed patent infringement lawsuits against three competitors over their proposed generics for Cibinqo, used to treat dermatitis.

Biocon Ltd., Changzhou Pharmaceutical Factory and Micro Labs Ltd. notified Pfizer in March that they were seeking approval for their Abrocitinib tablet products, according to Pfizer’s three complaints filed Thursday in the US District Court for the District of Delaware. The companies informed Pfizer that its patents protecting the medication were invalid or would not be infringed by their generics, Pfizer said in its complaints.

The drug giant said the generic products by all three companies would infringe ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.